DYAI News and Press, Dyadic International Inc. From 01/02/24

JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and...

Some of the best and brightest trends and innovators from the Benchmark Company’s 12th Annual Discovery Conference were featured in a recent Nasdaq news article written by Ari Zoldan , CEO of Quantum Media Group and Adjunct Professor at Yeshiva University. The piece shines the spotlight...

The Benchmark Company’s Discovery Conference was featured in a recent Nasdaq news article written by Ari Zoldan , CEO of Quantum Media Group and Adjunct Professor at Yeshiva University. The piece, titled “Some of the Best Ideas from the 12th Annual Benchmark Discovery Conference,...

JUPITER, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and...

Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant protein C1-cell produced antigen was both safe and well-tolerated No Serious Adverse Events reported Final Clinical Study Report available in the coming weeks ...

JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioprod...

2023-11-08 23:23:08 ET Dyadic International, Inc. (DYAI) Q3 2023 Earnings Conference Call November 8, 2023 05:00 p.m. ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business...

2023-11-08 17:31:16 ET More on Dyadic International Seeking Alpha’s Quant Rating on Dyadic International Historical earnings data for Dyadic International Financial information for Dyadic International For further details see: Dyadic International ...

Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme products DYAI-100 Phase 1 clinical trial top-line results expected in December 2023 New research collaboration with Vaccine and Imm...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...